Trial reportBlood2012
The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia.
Trial report in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00128713 (Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients), which is not on this map. Cited by 41 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Who cites it
41 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Transfusion of blood components in pediatric age groups: an evidence-based clinical practice guideline adapted for the use in Egypt using 'Adapted ADAPTE'.Annals of hematology · 2024Guideline
- Platelet storage duration and its clinical and transfusion outcomes: a systematic review.Critical care (London, England) · 2018Pooled it
- Pathogen-reduced platelets for the prevention of bleeding.The Cochrane database of systematic reviews · 2017Pooled it
- Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.The Cochrane database of systematic reviews · 2015Pooled it
- Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.The Cochrane database of systematic reviews · 2015Pooled it
- Retrospective cohort studies of repeat donors reveal donor-dependent variability in the recovery of transfused platelets.Transfusion · 2020Trial
- Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial.Blood advances · 2018Trial
- Transfusion-related adverse events in the Platelet Dose study.Transfusion · 2015Trial
- Associations of blood donor and product characteristics with platelet transfusion outcomes.Blood advances · 2026Article
- The evolving landscape of platelet therapy: risks, innovations, and clinical judgment.Annals of hematology · 2026Review
- Posttransfusion recovery, quality, and metabolism of short- and long-term stored platelets during controlled inflammation.Blood advances · 2025Article
- Nomogram for the Therapeutic Efficacy of Apheresis Platelet Transfusion in Hematologic Patients.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Platelet Transfusions: Current Practices and Emerging Alternatives in the United States.Life (Basel, Switzerland) · 2025Review
- Hemostatic conditions following autologous transfusion of fresh vs stored platelets in experimental endotoxemia: an open-label randomized controlled trial with healthy volunteers.Research and practice in thrombosis and haemostasis · 2024Article
- Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients.Blood advances · 2024Article
- Associations between ABO non-identical platelet transfusions and patient outcomes-A multicenter retrospective analysis.Transfusion · 2023Article
- Article
- The supply chain of blood products in the wake of the COVID-19 pandemic: Appointment scheduling and other restrictions.Transportation research. Part E, Logistics and transportation review · 2022Article
- Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress.Research and practice in thrombosis and haemostasis · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Platelet characteristics, such as platelet dose, platelet source (apheresis vs pooled), platelet donor-recipient ABO compatibility, and duration of platelet storage, can affect posttransfusion platelet increments, but it is unclear whether these factors impact platelet transfusion efficacy on clinical bleeding. We performed secondary analyses of platelet transfusions given in the prospective randomized Platelet Dose Study, which included 1272 platelet-transfused hematology-oncology patients who received 6031 prophylactic platelet transfusions. The primary outcome of these analyses was time from first transfusion to first World Health Organization ≥ grade 2 bleeding. Platelet transfusion increments were assessed at 0.25 to 4 hours and 16 to 32 hours after platelet transfusion. There were 778 patients evaluable for analysis of time to bleeding. Adjusted models showed that randomized dose strategy, platelet source, ABO compatibility, and duration of storage did not predict this outcome. Platelet increments were generally higher for transfusions of apheresis platelets, ABO-identical platelets, and platelets stored 3 days versus 4 to 5 days. Thus, although platelet source, ABO compatibility, and duration of storage exert a modest impact on both absolute and corrected posttransfusion platelet increments, they have no measurable impact on prevention of clinical bleeding. This trial was registered at www.clinicaltrials.gov as #NCT00128713.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.